Ovid Therapeutics Inc. OVID

On August 13, Ovid Therapeutics (NASDAQ:OVID) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates. The biopharmaceutical company, which focuses on treatments for brain disorders, used the update to lay out progress on two clinical programs, a leadership shakeup, and a deal that hands off one of its […]

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ETH.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET Webcasts of the pre

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA newly-formed portfolio company with funds advised by Perceptive Advisors acquired global rights to soticlestat; Ovid secured equity in the company and the potential to receive regulatory and sales milestone payments and royalties upon successStrengthened executive leadership team with appointment of Kev

Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to lead business and corporate development functions, as well as strategic partnerships. Most recently, Norrett served as chief […]

Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovid’s financial operations, following Jeffrey Rona’s transition to an advisory roleEliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric medici

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026. “Anna is a visionary, passionate physician-scientist and entrepreneur whose work sits at the intersection of groundbreaking nodal biology and therapeutic innovation,” said Meg Al

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studiesAnnounced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), c

Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best fast growing penny stocks to buy right now. On April 9, H.C. Wainwright raised the firm’s price target on Ovid Therapeutics to $4 from $2 with a Buy rating on the shares. The company’s OV4071 oral KCC2 candidate is entering the clinic imminently, triggering warrant exercises. […]

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously. During the event independent expert clinicians and translational experts as well as Ovid’

Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct activator OV4071, new safety and tolerability data for its seizure candidate OV329, and a $60 millio

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures and an open-label, proof-of-concept studyExpanding OV329 development to complementary indications in tuberous sclerosis complex seizures and infantile spasms, supported by a $60.0 million private placementOV4071, a first-in-class, oral KCC2 direct activator, received Human Research